Zura Bio Ltd
ZURA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001855644
Insider trades, last 90 days
None
- No open-market purchases or sales were filed in the last 90 days.
13F holders, Q2 2026
95
- +1 vs. Q1 2026
- Total value $428.85M
Superinvestors holding ZURA
0
- None of the superinvestors held ZURA at the end of Q2 2026.
Price chart
Latest insider trades
View all: Latest insider tradesOpen-market purchases and sales by ZURA insiders, newest first.
| Filed (ET) | Trade date | Insider | Transaction | Shares | Avg price | Value | Shares after | Holding change | Filing |
|---|---|---|---|---|---|---|---|---|---|
| Mar 2, 20265:55 PM ET | Feb 26, 2026 | Blavatnik Len and 3 others10% Owner | PPurchaseClass A Ordinary Shares | +2M | $6.25 | +$12.5M | 6.55M | +43.9% | SEC |
| Nov 27, 2024 | Nov 25, 2024 | Thiara ParvinderDirector | SSaleClass A Ordinary Shares | −1M | $2.73 | −$2.73M | 0 | −100.0% | SEC |
| Sep 13, 2024 | Sep 11, 2024 | Thiara ParvinderDirector | SSaleClass A Ordinary Shares | −3.8M | $2.70 | −$10.26M | 1M | −79.1% | SEC |
| Sep 6, 2024 | Sep 4, 2024 | Sidhu SomeitDirector | SSaleClass A ordinary shares | −51.73K | $3.87 | −$200.19K | 2.09M | −2.4% | SEC |
| May 23, 2024 | May 17, 2024 | Ploos van Amstel ArnoutDirector | PPurchaseClass A ordinary shares | +80K | $6.20 | +$496K | 100K | +400.0% | SEC |
Top 5 13F holders, Q2 2026
View all: Top 5 13F holders, Q2 2026The largest institutional positions in ZURA at the end of Q2 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| SUVRETTA CAPITAL MANAGEMENT, LLC | 9,443,001 | $55.71M | 1.17% | +376,000+4.1% | Added |
| VR Adviser, LLC | 6,434,990 | $37.97M | 1.15% | 00.0% | Unchanged |
| MPM Oncology Impact Management LP | 4,472,843 | $26.39M | 1.61% | +4,472,843 | New |
| GREAT POINT PARTNERS LLC | 4,215,930 | $24.87M | 5.86% | 00.0% | Unchanged |
| JPMORGAN CHASE & CO | 4,354,715 | $24.52M | 0.00% | −104,136−2.3% | Reduced |